Title:
Obesity, metabolic disease and the pancreas – Quantitative imaging of pancreatic fat

Running title:
Quantitative imaging of pancreatic fat

Type of manuscript:
Review article

Author names:
Naomi S Sakai
Qualifications: MRCS MA
Affiliations: University College London (UCL) Centre for Medical Imaging, Division of Medicine, UCL, London, UK

Stuart A Taylor
Qualifications: MRCP FRCR MD
Affiliations: University College London (UCL) Centre for Medical Imaging, Division of Medicine, UCL, London, UK

Manil D Chouhan (corresponding author)
Qualifications: MRCS FRCR PhD
Affiliations: University College London (UCL) Centre for Medical Imaging, Division of Medicine, UCL, London, UK

Full address: UCL Centre for Medical Imaging
2nd Floor Charles Bell House
43-45 Foley Street
London
W1W 7TS

Acknowledgements:
NSS is supported by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. SAT is a NIHR Senior Investigator.
Obesity, metabolic disease and the pancreas –
Quantitative imaging of pancreatic fat

Review article

Running title: Quantitative imaging of pancreatic fat
Abstract

The association between pancreatic fat, obesity and metabolic disease is well-documented, and although a potentially exciting target for novel therapies, remains poorly understood. Non-invasive quantitative imaging-derived biomarkers can provide insights into pathophysiology and potentially provide robust trial endpoints for development of new treatments.

In this review, we provide an overview of the pathophysiology of non-alcoholic fatty pancreas disease and associations with metabolic factors, obesity and diabetes. We then explore approaches to pancreatic fat quantification using ultrasound, computed tomography and magnetic resonance imaging, reviewing the strengths, limitations and current published evidence in the assessment of pancreatic fat. Finally, we explore the broader challenges of pancreatic fat quantification as we move toward translating these methods into the clinical setting.
**Fat and the Pancreas**

Obesity, as defined by Body Mass Index (BMI) exceeding 30 kg/m², is a major global economic and public health challenge, with the UK prevalence increasing from 15% to 27% since 1993 and expected to reach 35% by 2030. Obesity is a known cause of ectopic fat accumulation in organs including the pancreas. Fatty infiltration of the pancreas (pancreatic steatosis) in obesity was first described in 1933 and has since been linked to pancreatitis, the metabolic syndrome and type 2 diabetes mellitus (T2DM). The pathophysiology of pancreatic steatosis and its sequelae are less well understood than in the liver, and remain an area of ongoing research. Pancreatic steatosis is linked to a number of congenital and acquired factors including cystic fibrosis, age, alcohol excess, viral infections and drugs, but the association with metabolic factors (obesity and T2DM) have driven renewed interest. Research has been hampered by the lack of standardised nomenclature, with the use of various terms, for example, pancreatic steatosis, fatty pancreas, fatty infiltration and pancreatic lipomatosis. Recently, however, the term non-alcoholic fatty pancreas disease (NAFPD) has gained acceptance in describing pancreatic steatosis in association with obesity and the metabolic syndrome. Whilst a recent meta-analysis quantified normal mean pancreatic fat at 4.5±0.9% (based on pooled data across multiple MR methods and imaging modalities), progress has also been slowed by the lack of a precise consensus threshold on the upper limit of normal pancreatic fat content.

Histologically, NAFPD is a heterogeneous process, characterised by increased intracellular lipid accumulation and adipocyte infiltration in the pancreatic tissue. Islet cells themselves are thought to be resistant to fatty infiltration but it has been suggested that the overall process is similar to that seen in the liver (where NAFLD progresses to NASH), with NAFPD progressing to non-alcoholic fatty steatopancreatitis (NASP) (figure 1). Under conditions of oxidative stress, fat-derived cytokines are released and result in localised inflammation and organ dysfunction. In addition, adipose itself has endocrine capabilities, producing adipocytokines, including leptin, adiponectin, tumour necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and monocyte chemotactic protein-1 (MCP-1). Recruited macrophages in turn produce IL-1β and myeloperoxidase (MPO), which further exacerbate the inflammatory process. This has led to the hypothesis that NAFPD may increase the risk of developing pancreatitis (and exacerbate its severity), pancreatic cancer, beta-cell dysfunction and the development of T2DM.
Metabolic factors, Type 2 Diabetes Mellitus and NAFPD

The metabolic syndrome is a group of risk factors for cardiovascular disease, T2DM and stroke, which includes obesity, dyslipidaemia, hypertension and raised fasting blood glucose. NAFPD and its relation to age, BMI, atherosclerosis and diabetes was first described in post-mortem studies. Current data suggest that fat distribution is a better marker of metabolic risk than obesity itself; this has resulted in great interest in the pancreas as a site of ectopic fat deposition and its role in insulin resistance. More recent research has demonstrated an association between NASH and NAFPD and identified a 2-fold increase in the risk of metabolic syndrome in patients with NAFPD.

Ectopic fat accumulation in skeletal muscle and liver is linked to insulin resistance and pancreatic Islet of Langerhans beta-cell dysfunction. Insulin resistance coupled with progressive beta-cell dysfunction is a hallmark of T2DM. The correlation between patients with NASH and NAFPD has also driven interest in lipid accumulation in the pancreas as a cause of impaired beta-cell insulin secretion. The effect of pancreatic fat on insulin resistance and pancreatic beta-cell dysfunction has been investigated in animal and human studies. Pancreatic fat content in humans is associated with BMI, insulin resistance and the metabolic syndrome. It is proposed that there is a combined destructive effect of increased free fatty acids and NAFPD on pancreatic beta and islet cell function which leads to hyperglycaemia. However, the evidence as to whether fat accumulation in the pancreas causes beta-cell dysfunction has been inconsistent, particularly in the absence of intra-islet cell lipid accumulation. Whilst some studies have shown that beta-cell function is negatively associated with pancreatic fat content in non-diabetic subjects or those with prediabetes others have suggested no relationship. The association between NAFPD and beta-cell dysfunction is thought to be more complex with factors in addition to pancreatic fat being important once diabetes occurs. Interestingly, there is a positive correlation between the duration of T2DM and the pancreatic fat content. In addition to fat content, pancreatic volume is believed to influence the risk of diabetes. Individuals with a large pancreatic volume are thought to have a more sizeable reservoir of beta-cells and greater capacity to withstand the various factors that contribute to the development of diabetes. T2DM is thus associated with a smaller pancreatic volume and greater pancreatic fat content relative to normoglycaemic patients without T2DM.

Quantitative methods for imaging the pancreas
The deep retroperitoneal location of the pancreas means that there are challenges to studying it noninvasively. This, coupled with its variable shape, often ill-defined boundaries, heterogeneous fat distribution\textsuperscript{28} and upper abdominal location (with susceptibility to motion artefact), mean that quantitative assessment of pancreatic volume and fat content is challenging across all imaging modalities.

**Ultrasound (US)**

The pancreas can be assessed using transabdominal or endoscopic ultrasound (EUS). The pancreas can usually only be partially visualised with transabdominal US because of overlying stomach/small intestine gas. EUS allows the transducer to be placed in close proximity to the pancreas and therefore has the potential to provide more detailed images of the whole organ but has the major disadvantage of being invasive. Studies have compared the echotexture of the pancreas to the kidney,\textsuperscript{6,21,29–33} liver\textsuperscript{33} or spleen,\textsuperscript{16} with the presence of increased pancreatic echogenicity indicative of fatty infiltration. Trans-abdominal US is a relatively quick and relatively cheap method of imaging the pancreas, is well-tolerated and does not involve ionising radiation. However, it is operator dependent (reported mean interobserver agreement for ultrasound diagnosis of fatty pancreas as low as 72\%)\textsuperscript{21} and the pancreas cannot always be visualised (up to 14.5\% of all cases),\textsuperscript{31} particularly in obese patients. Crucially, the echotexture of the liver or kidney which the pancreas is compared with may be abnormal and as such US echogenicity or echogenicity ratios do not provide reliable quantitative information.

**US elastography**

Elastography measures biomechanical tissue response to an applied physical stress. The deep intra-abdominal location of the pancreas precludes the use of transient elastography, but acoustic radiation force impulse (ARFI) can be used to deliver localised stress under standard B-mode US imaging guidance. Fat deposition is thought to make the liver softer so that stiffness reduces with progressive hepatic steatosis\textsuperscript{35}. Application in the pancreas has been more limited\textsuperscript{36,37} – studies have hypothesised that reductions in stiffness occur with progressive pancreatic steatosis but results have been conflicting, with one study finding reduced pancreatic stiffness in a group of patients with pancreatic insufficiency in cystic fibrosis\textsuperscript{38} and another finding no difference between normal pancreatic tissue and NAFPD\textsuperscript{37}. Nonetheless, this is a growing area and larger-scale studies may yet yield useful applications.
for NAFPD, albeit limited by the small size of the ARFI region-of-interest (ROI) and difficulties with pancreatic visualisation.

**Computed tomography (CT)**

CT is well-suited to imaging the pancreas because of its shorter acquisition time, availability and widespread clinical use. However, the use of ionising radiation and intravenous contrast compromise its use in research, particularly if serial studies are required. Contraindications to intravenous contrast including renal impairment (pertinent in patients with diabetic nephropathy) represent major challenges to use in the assessment of patients with diabetes.

Fatty infiltration of the pancreas is appreciable on CT when there is an increase in interlobular fat (figure 2), but there are no consensus criteria for the CT diagnosis of pancreatic steatosis. A variety of techniques have been applied in the literature including calculating pancreatic attenuation on unenhanced images using three ROIs placed on the pancreatic head, body and tail. Using this method to derive mean pancreatic attenuation, a threshold of <36 Hounsfield Units (HU) has been proposed for the diagnosis of pancreatic steatosis.\(^{39}\) Other studies have used the ratio of pancreatic to splenic attenuation on unenhanced and post-contrast arterial and portal venous phase CTs to demonstrate significant correlations with histological fat fractions.\(^{27,39}\) More sophisticated methods of segmentation, including the use of semi-automated techniques to define pancreatic tissue margins, with subsequent histogram analysis with local thresholding have also been proposed.\(^{27}\) Ectopic fat in the pancreas is not evenly distributed throughout the organ\(^{28}\) and certain patterns of fatty infiltration may be of specific clinical relevance. CT is unable to distinguish between fat in adipocytes and intracellular fat in parenchymal cells so a given ROI may not accurately represent the total organ fat. The pancreatic margin can be poorly defined on CT, particularly in the presence of atrophy, which complicates the placement of ROIs and may result in partial volume effects.

**Magnetic Resonance Imaging (MRI)**

Magnetic resonance (MR) signal from biological tissue arises predominantly from protons within water and fat molecules. Protons within either molecule exist within slightly different chemical environments, giving rise to small differences in their resonance frequencies which can be exploited for quantification.\(^{40}\) MR approaches to fat quantification that have been applied to the pancreas include spectroscopy and imaging methods with early efforts.
focussing on chemical-shift imaging and evolving into spectral-spatial fat selective, multi-point Dixon and ultimately proton-density fat fraction (PDFF) techniques.

**Magnetic Resonance Spectroscopy**

MR spectroscopy (MRS) is often considered gold-standard for non-invasive pancreatic fat quantification. The technique requires the user to manually position a voxel (usually 2.0 x 1.0 x 1.0 cm, i.e. 2.0 cm$^3$) to contain as much pancreatic tissue as possible (avoiding blood vessels and the main pancreatic duct).\textsuperscript{20,25,41–44} MRS acquired using either point-resolved spectroscopy (PRESS) or stimulated echo acquisition mode (STEAM) sequences is used to derive a resonance frequency histogram (spectrum) of the constituent proton signals (figure 3). Measured raw spectra are then fitted with the expected spectrum and the relative area under spectral peaks of interest (arising from water peaks and detectable peaks for chemical environments of protons within fat) are used to estimate voxel fat fraction.

Deriving spectra from such a small voxel requires good quality local shimming and multiple averages, thereby extending acquisition time. Susceptibility to respiratory motion and cardiac motion artefact (from adjacent pulsatile arterial vessels) is therefore a major challenge. Voxel contamination with extra-pancreatic tissue (usually visceral or peritoneal fat) compromises shim quality and can cause significant alterations in measured spectra. Early studies reported dramatic increases in lipid signal from some measured spectra likely secondary to subject deep breathing.\textsuperscript{20} Respiratory and cardiac gating have been shown to reduce this challenge but extend acquisition time (as much as 30 minutes per voxel).\textsuperscript{42} Even with respiratory gating, data exclusion rates of as much as 8% due to motion artefact have been reported.\textsuperscript{44} As imaging protocols are likely to require multi-voxel measurements and additional sequences, prolonged acquisition times can conversely result in subject discomfort thereby exacerbating patient motion. Operator expertise in placement of the MRS voxel is also required. The spatial mismatch arising from the time between anatomical imaging used to plan the MRS study and MRS acquisition have also been reported as a source of error.\textsuperscript{45} An issue common to MRS and other imaging-based methods of MR fat quantification arises from the fitting of raw spectra for quantification. Implicit in the fitting process is prior knowledge of where spectral peaks are likely to occur, which is dependent on the chemical environment of intracellular fat and will vary from tissue to tissue. A single broad 1.3 ppm (methylene group) peak has been proposed for the pancreas, but the same peak is also seen in extracellular fat and it is difficult to be certain if measured pancreatic spectra are the result of
voxel contamination or arise from intralobular pancreatic tissue itself (figure 3). \cite{41} Fitting to incorrect spectra, however has been shown to have significant effects on quantification. \cite{46,47}

Finally, intralobular pancreatic fat content is very low and prone to noise-related errors. Even when diabetic MRS pancreatic fat measurements are increased, this is likely to represent increased fatty infiltration (i.e. extralobular fat within the MRS voxel) and age-related loss of beta-cell mass (and parenchymal volume) rather than impaired beta-cell function arising from a true increase in intralobular fat. \cite{41}

Because of these technical challenges, reported repeatability and reproducibility of pancreatic MRS measurements has been poor, and consistently inferior to that measured in the liver. \cite{20}

Moreover, reported associations between MRS derived measurements of pancreatic fat and metabolic factors have been conflicting. MRS studies have confirmed that pancreatic fat is increased in diabetes, obesity \cite{20,42} and also in the setting of impaired glucose tolerance. \cite{25} No association with visceral fat has been reported, \cite{20,25} and data on the association with beta-cell function has been inconsistent. \cite{20,44}

**Chemical-shift MRI**

MR imaging methods have the major advantage of being able to map quantitative data across an entire imaged volume (and not exclusively within a small MRS voxel). More complex hypotheses pertaining to distribution of fat within the pancreas, adjacent abdominal viscera and more distant tissue can then be probed, particularly as MR imaging methods are based on shorter acquisition times. Faster acquisition times are a major strength but also result in limitations to pancreatic fat quantification.

Chemical-shift imaging (CSI) involves acquisition of imaging signal at two or more echo times spaced to match the chemical shift between the main fat and water peaks. Generated ‘in-phase’ and ‘out-of-phase’ images (where fat and water constructively and destructively interfere, respectively), can then be subtracted to estimate fat content. \cite{48} Qualitative assessment of fat content is feasible, but quantification of tissue fat content is limited by errors arising from background magnetic field (B\textsubscript{0}) inhomogeneity, and difficulties with the quantification of very high/low fat fraction measurements. \cite{40,49} This is a major challenge in a small organ such as the pancreas, where small volume islands of pancreatic parenchymal tissue, surrounded by infiltrating extralobular fat are prone to quantification errors arising from high extralobular fat content, low pancreatic parenchymal fat and partial voluming
Studies using CSI have reported correlations between pancreatic and visceral fat, but no association with insulin resistance, BMI, subcutaneous adiposity or other metabolic syndrome features once data was adjusted for the effects of age, gender and visceral adipose tissue.\textsuperscript{50,51} Several approaches were proposed to overcome the limitations of CSI. Spectral-spatial fat selective imaging was developed to overcome the challenge of $B_0$ inhomogeneity, errors arising from noise when quantifying small fat fractions and imaging artefacts that arise at fat-water interfaces (seen at pancreatic tissue boundaries). Using good quality local shimming, spectral-spatial fat selective imaging applies spectral-selective and spatial-selective excitations within a multi-slice imaging scheme, to generate fat fraction maps.\textsuperscript{52–54} No correlation between spectral-spatial fat selective pancreatic and liver fat has been reported,\textsuperscript{55} however negative correlations between pancreatic fat and insulin secretion were observed in patients with impaired glucose tolerance.\textsuperscript{24}

Multi-point Dixon methods were developed to overcome the challenge of $B_0$ inhomogeneity and ambiguities arising from fat fraction measurements of greater than 50%. Standard CSI relies on signal magnitude acquired from at least two echo times; by imaging at three or more echo times, complex data (including both magnitude and phase images) can be used to map $B_0$ and correct for inhomogeneities and estimate fat fractions exceeding 50%.\textsuperscript{56} This is important as while pancreatic intralobular fat fractions are low, infiltrating (extra and interlobular) fat is likely to have fat fractions greater than 50%.

Multi-point Dixon methods have been applied to the pancreas with varying additional modifications for improvement of measurement accuracy. MRS validation studies have demonstrated a tendency to overestimate pancreatic fat fraction,\textsuperscript{43} while histological validation studies have reported wide Bland-Altman limits of agreement (over 16%).\textsuperscript{57}

Several studies have reported increased multi-point Dixon pancreatic fat in patients with T2DM,\textsuperscript{41,58,59} with further studies confirming associations between pancreatic fat and age, and weak but significant associations with visceral adiposity and liver fat in adult and paediatric cohorts.\textsuperscript{60,61} Non-uniform increases in multi-point Dixon pancreatic fat fraction in diabetic patients have also been reported, although this may reflect increasing inter lobular
fatty infiltration/atrophy. Contrastingly, single slice whole pancreas (rather than ROI) segmentation demonstrated no significant difference in T1DM pancreatic fat relative to normal controls. Large-scale studies however have reported associations with obesity, hypertriglyceridaemia and increased insulin resistance (although these associations were stronger for hepatic fat). A small but interesting study demonstrated multi-point Dixon pancreatic fat reductions following an 8 week low calorie diet regime in diabetic patients.

**Proton Density Fat Fraction mapping**

PDFF mapping addresses limitations of multi-point Dixon quantification, many of which are specifically relevant to pancreatic imaging (figure 5). T1 weighting is altered in chronic pancreatic inflammation and can amplify the relative fat signal. By ensuring the acquisition flip angle is as small as possible, errors introduced by T1 signal bias can be reduced. T2 and T2* can both be altered by pancreatic pathology (inflammation and pancreatic iron deposition respectively), furthermore decay of both during the acquisition will also affect fat quantification. The multi echo time acquisition can be used to measure the amount of T2 decay, estimate T2*, and correct for both of these in the fat fraction measurement. PDFF mapping also accounts for the spectral complexity of fat by modelling fat signal using multi-peak fat models, rather than a simple single peak model. Finally, low fat fractions as seen in measurements of intralobular pancreatic fat, suffer from noise bias. Complex data containing positive and negative signal tend to underestimate, whilst magnitude-based methods tend to overestimate, true fat fraction. Phase constraining/magnitude discrimination methods have been applied to minimise these errors.

Pancreatic PDFF validation data with MRS has been modest, explained in part by some of the limitations of pancreatic MRS, and the non-uniform distribution of fat through the pancreas as measured with PDFF. The association of pancreatic PDFF with diabetes is controversial, with large sample studies reporting increased and unchanged levels of pancreatic fat. Association with insulin resistance has also been reported, as have modest associations with visceral and subcutaneous adiposity.

**Challenges and opportunities**

Unlike US and CT, the dependence of MR signal on fat content is a major strength underpinning its use in fat quantification. By avoiding the observer variability of US and ionising radiation of CT, MRI has the potential to combine spatial anatomical and
quantitative data safely and accurately. The variety of different MRI methods used in the
literature is however a challenge, and whilst these catalogue methodological evolution, they
also conceal important methodological differences that preclude inter-study comparisons and
compromise the pooling of data for meta-analyses.\(^9\)

PDFF MRI currently represents the most evolved method of MR fat quantification but is not
without its limitations. The design of PDFF sequences is tailored towards the measurement
of hepatic (and not pancreatic) fat and as such there is scope for optimisation that may lead to
more robust quantification. The spectral complexity of pancreatic fat has been under-
investigated, with current presumed in vivo spectra prone to contamination from extralobular
fat (figure 3). Surgical specimens for ex vivo pancreatic MRS may be a potential approach
but are also likely to include significant extralobular fat (especially in the presence of fatty
infiltration). Closely linked to this challenge is the lack of reliable reference standard data for
validation. Histological sampling is invasive and tends to be derived from surgical
specimens (unlike liver biopsies which are more routine and require only minimally invasive
image guidance). Measured pancreatic fat fractions are commonly lower than those reported
in the liver and are therefore more susceptible to noise. Although the PDFF approach
includes methods to minimise noise, it is feasible that a more robust approach is required to
deal with the higher levels of noise affecting pancreatic fat measurements.\(^{70}\)

Approaches to pancreatic segmentation are another area with significant potential for
optimisation. Previously discussed studies have classically placed ROIs in the head, body
and tail of pancreas, with various specifications to avoid duct, vessel or extra pancreatic fat.
Variations in the distribution of fat across the gland have not been consistently described, but
this may reflect sampling error. Whole organ segmentation is difficult, as the pancreas can
span multiple slices, have ill-defined margins and require significant operator
experience/expertise. Recent combinations of manual segmentation with thresholding have
shown promising results with improved inter-observer variation.\(^{76}\) Pancreatic disease
however is associated with dramatic morphological changes including fatty infiltration and
atrophy. Changes in the distribution of intralobular, interlobular and extralobular pancreatic
fat are regularly seen on cross-sectional imaging but remain poorly understood (figure 6).
Improved segmentation methods represent a major tool to address new hypotheses
surrounding the distribution of pancreatic fat across these compartments. The development
of automated methods for whole organ and multicompartiment segmentation using machine
learning methods is a promising area. Whilst to date predominantly focussed on CT,\textsuperscript{77} machine learning has the potential to yield powerful tools for quantitative pancreatic MRI.\textsuperscript{78} Finally, little is known if measured changes in pancreatic fat are due to increases in intracellular fat, parenchymal atrophy or both, or indeed the relationship between and significance of these very different pathophysiological processes in the evolution of metabolic disease and obesity. Recent work on novel sub-phenotypes within T2DM for example, may yet help to clarify contradictory findings that have emerged from previous pancreatic imaging studies.\textsuperscript{79} Alongside this, the development of better tools for the assessment of pancreatic fat combined with improvements in our understanding of the microscopic pathophysiology of pancreatic disease will together help to advance the treatment approaches for metabolic disease, diabetes and obesity.
References:


54 Schick F, Forster J, Machann J, Huppert P, Claussen CD. Highly selective water and


70 Begovatz P, Bierwagen A, Lundbom J, Roden M. Pancreatic triacylglycerol


Figure 1: Pathophysiological mechanisms for non-alcoholic fatty pancreas disease

Intracellular accumulation of lipid (1) is thought to precede the rise in pancreatic tissue adipocytes (2). Subsequent oxidative stress leads to the release of adipokines and cytokines (4) which trigger an inflammatory response (5) that is ultimately thought to drive beta-cell dysfunction lead to type 2 diabetes mellitus.

Figure 2: Complete fatty replacement of the pancreas

Extreme pancreatic steatosis and atrophy – the residual pancreas with presumed borders outlined (dashed white line). The main pancreatic duct is just visible with only minimal lobular tissue.

Figure 3: Magnetic Resonance Spectroscopy and the differing spectral complexity of pancreatic fat

MRS study planning (a) of the liver (i) and pancreas (ii), with corresponding spectra arising from the liver voxel (b) and pancreatic voxel (c). Note differing voxel sizes and the challenge of ensuring inclusion of purely pancreatic tissue within the MRS voxel (a, ii). The water peak is shown in both spectra (b, c) at 4.7 ppm (solid white arrow). Liver fat spectra (b) have been shown to demonstrate six peaks (at 5.3, 4.2, 2.75, 2.1, 1.3 and 0.9 ppm), while pancreatic fat spectra (c) are dominated by single 1.3 ppm methylene peak (clear white arrow). It is not known if this reflects genuine pancreatic fat content or contamination from extra-lobular fat.

Figure 4: Chemical-shift imaging and pancreatic fat quantification in the presence of fatty infiltration

In-phase (a) and out-of-phase (b) CSI in the presence of significant pancreatic fatty infiltration. Note the ‘india-ink’ artefact at fat-water interfaces on out-of-phase images (b), which when combined with in-phase imaging makes quantification in small islands of tissue prone to partial voluming errors.

Figure 5: Proton Density Fat Fraction imaging

Images derived from water-only and fat-only are used to generate a parametric fat fraction map across an axial slice. Note low pancreatic intra-lobular fat fractions (despite fatty
infiltration, white-dashed outline). Errors arising from intraluminal (solid black arrows) and peripheral gas (solid white arrows), result in incoherent pixelation.

**Figure 6: Pancreatic fat segmentation**

As the pancreas undergoes both fatty infiltration and atrophy, the significance of fat changes (shaded areas) in the intralobular (a), interlobular (b) and extralobular/peripancreatic (c) fat compartments are unknown. Inconsistencies in the way in which these have been reported/evaluated in the literature are a barrier to pooled meta-analyses and robust segmentation methods for quantifying each of these are an important challenge.
Figure 1

- Acinus
- Acinar cell capillary adipocyte
- Alpha-cell beta-cell duct
- Islet of Langerhans
- Intracellular lipid accumulation
- Rising pancreatic adipocytes
- Oxidative stress
- Adipokines: Leptin, Adiponectin, TNF-α, IL-6, MCP-1
- Cytokines
- Inflammation
- Macrophage recruitment
- IL-1β, MPO